Which femtech companies got investment?

This blog post has been written by the person who has mapped the femtech investment market in a clean and beautiful presentation

FemTech funding reached $2.6 billion in 2024, marking a 55% year-over-year increase as investors recognize the massive opportunity in women's health innovation.

From Future Family's $400 million fertility financing round to Hims & Hers' $1 billion debt issuance, the sector is attracting serious capital across fertility, diagnostics, menopause, and AI-driven healthcare solutions. Major biotech and pharma players are entering through strategic partnerships and acquisitions, while early-stage startups continue securing seed funding for breakthrough technologies.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which specific companies received funding in 2024 and early 2025, and how much capital did each raise?

The funding landscape in 2024-2025 shows clear winners across different sectors, with fertility and telehealth companies securing the largest rounds.

Future Family led the pack with a $400 million financing initiative in April 2025, establishing a subscription-based platform for IVF and egg-freezing treatments. This wasn't traditional venture capital but rather a programmatic fund designed to subsidize patient treatments through strategic partnerships with healthcare providers and insurers.

Hims & Hers took a different approach with a massive $1 billion convertible debt issuance in May 2025, featuring a 5-year maturity period convertible at the next equity round. TPG Growth and Wellington Management led this debt round to fuel nationwide expansion of their telehealth services covering sexual wellness, dermatology, and primary care.

ByHeart secured $72 million in Series C funding in April 2025 from Lux Capital and Sequoia Capital, targeting 20% ownership dilution with structured earn-out provisions. The infant nutrition company combines clinical research with clean-label manufacturing and personalized nutrition algorithms.

Other notable raises include Vitara's $50 million Series B at a $1.2 billion post-money valuation for hormone monitoring wearables, Overture Life's $20.6 million Series B for IVF automation technology, and Juniper Genomics' $4.6 million seed round for whole-genome embryo screening platforms.

Who are the most active investors in femtech, and which specific companies have they backed?

The investor landscape reveals both specialized femtech funds and major generalist VCs actively deploying capital across women's health startups.

Seedtable identifies 29 top global femtech investors including Google Ventures, Khosla Ventures, Blossom Capital, Storm Ventures, and Octopus Ventures, each bringing different sector expertise and geographic reach to their portfolio companies.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

What are the five most-funded femtech startups recently and what does each company actually do?

The top-funded companies represent diverse approaches to women's health, from financial innovation to direct clinical care.

Future Family ($400M, April 2025) operates a personalized fertility financing platform offering subscription-based payment plans for IVF treatments, egg freezing, and related procedures. Their model removes the upfront cost barrier by spreading expenses across monthly payments while partnering with fertility clinics nationwide.

Hims & Hers ($1B convertible debt, May 2025) provides telehealth services specifically targeting sexual wellness, dermatology, hair loss, and primary care through direct-to-consumer subscriptions. They manufacture generic medications in-house and offer virtual consultations, targeting both men and women's health needs.

ByHeart ($72M, April 2025) develops infant formula combining clinical research with clean-label manufacturing. They focus on personalized nutrition using organic ingredients and avoid synthetic additives found in traditional formulas, targeting health-conscious parents willing to pay premium prices.

Vitara ($50M, November 2024) creates wearable hormone-monitoring devices providing real-time feedback on menstrual cycles, fertility windows, and hormonal fluctuations. Their technology enables precise tracking without daily testing, appealing to women trying to conceive or managing reproductive health.

Juniper Genomics ($4.6M, June 2025) operates the first whole-genome embryo screening platform integrating genomic and transcriptomic sequencing. This technology helps IVF patients identify the healthiest embryos for transfer, potentially improving success rates and reducing miscarriage risks.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

Which companies secured the largest single funding rounds and under what specific terms?

The largest funding rounds reveal different strategies for scaling femtech businesses, from debt financing to programmatic funding models.

Hims & Hers' $1 billion convertible debt represents the largest single raise, structured with a 5-year maturity period and conversion rights at the next equity round. This debt financing allows rapid expansion without immediate dilution, giving the company flexibility to scale operations and marketing spend while maintaining control.

Future Family's $400 million financing initiative operates differently as a programmatic fund rather than traditional venture capital. The funding subsidizes patient treatments through partnerships with employers and insurance providers, creating a sustainable model where the fund recycles as patients complete treatments.

ByHeart's $72 million Series C involved 20% ownership dilution with structured earn-out provisions tied to revenue milestones. Lux Capital and Sequoia negotiated performance-based terms allowing additional funding if the company hits specific growth targets in the infant nutrition market.

Vitara's $50 million Series B at a $1.2 billion post-money valuation demonstrates strong investor confidence in hormone monitoring technology. General Catalyst and Google Ventures led the round, betting on the wearables market expanding beyond fitness into reproductive health tracking.

Which geographic regions attracted the most femtech investment in 2024-2025?

North America dominates femtech investment with over 50% of total deal value in 2024, driven by U.S. unicorns and strong partnerships between startups and established healthcare systems.

The United States benefits from favorable regulatory environments for digital health, large corporate health benefits budgets, and sophisticated venture capital networks specializing in healthcare technology. Major rounds like Future Family's $400 million and Hims & Hers' $1 billion debt issuance demonstrate the scale American companies can achieve.

Europe secured €339 million across 47 deals in 2024, significantly outperforming the 2021 levels. The United Kingdom leads European investment with 31.8% market share, boosted by Flo Health achieving unicorn status and increased government research grants supporting women's health innovation.

Asia Pacific represents an emerging market with India showing notable seed-stage activity, though overall funding dropped to $8.7 million in 2024. The region faces challenges including regulatory complexities and cultural barriers to women's health discussions, limiting large-scale investment compared to Western markets.

EMEA showed more stable funding patterns with only a 50% decline from 2021-2023 peaks compared to North America's 66% drop, suggesting stronger resilience in European markets. Early-stage focus remains on diagnostics and chronic women's health conditions rather than consumer wellness applications.

Are major healthcare, biotech, or pharma companies investing in or acquiring femtech startups?

Corporate involvement in femtech has accelerated through strategic partnerships, direct investments, and selective acquisitions targeting specific therapeutic areas.

Pharmavite's $425 million acquisition of Bonafide demonstrates big pharma's interest in menopause care devices and supplements. This deal signals corporate recognition that women's health represents an underserved market with significant commercial potential, especially as baby boomers age into menopause.

Fresenius and IVI RMA's purchase of Boston IVF operations shows healthcare systems consolidating fertility services. These acquisitions combine established clinical networks with innovative technologies, creating integrated platforms serving patients from diagnosis through treatment.

Strategic VC arms from major corporations actively invest in femtech startups. Google Ventures backs Maven Clinic, CVS Health Ventures supports teletherapy platforms, and Johnson & Johnson Innovation, Novartis Venture Fund, GE HealthCare, and Roche Venture Fund regularly participate in femtech funding rounds.

Partnership models are emerging as alternatives to acquisitions. Bayer collaborates with Impli for early-stage R&D, while Roche funds AI diagnostic companies. These partnerships allow corporations to access innovation without full acquisition costs while providing startups with validation and distribution channels.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

If you want to build or invest on this market, you can download our latest market pitch deck here

What new technologies or research breakthroughs are being financed in femtech?

Investment is flowing toward AI-powered diagnostics, advanced wearables, digital therapeutics, and genomics technologies that address previously unsolved women's health challenges.

AI-powered diagnostic tools are attracting significant funding, with companies like Illumicell developing portable fertility analyzers and Leyla Dystatic creating breast cancer detection systems using deep learning algorithms. These technologies promise to make specialized diagnostic capabilities accessible outside traditional clinical settings.

Advanced wearable technology extends beyond basic fitness tracking to hormone monitoring and therapeutic interventions. Vitara's real-time hormone tracking and Fizimed's pelvic floor rehabilitation devices represent the next generation of connected health devices specifically designed for women's physiology.

Digital therapeutics companies are securing funding for evidence-based software treatments. Amara Therapeutics develops overactive bladder digital therapeutics, while Trellis Health creates personal health data platforms that integrate multiple data sources for comprehensive care management.

Genomics breakthroughs include Juniper Genomics' whole-genome embryo screening technology and Cacto Health's lymphedema detection systems. These companies use advanced sequencing and AI analysis to provide insights previously requiring expensive laboratory testing or invasive procedures.

Which specific femtech sectors are attracting the most investment capital?

Fertility and IVF dominate both deal volume and capital allocation, reflecting the sector's commercial maturity and clear revenue models.

Precision medicine targeting autoimmune and cardiometabolic conditions affecting women saw $3.6 billion in funding in 2024, up from $1.4 billion in 2023, indicating growing recognition that many diseases affect women differently than men.

Which corporate VCs and strategic partners are consistently active in femtech deals?

Corporate venture capital arms from healthcare giants are becoming regular participants in femtech funding rounds, bringing both capital and strategic value to portfolio companies.

Johnson & Johnson Innovation focuses on diagnostic technologies and digital health platforms that complement their pharmaceutical pipeline. They typically invest $5-15 million in Series A and B rounds for companies developing women's health solutions with clear regulatory pathways.

Novartis Venture Fund targets startups developing novel therapeutics or diagnostic tools for women's health conditions. Their investments often include partnership options for clinical development and global distribution through Novartis' existing networks.

GE HealthCare invests in medical imaging and diagnostic technologies, particularly companies developing AI-powered solutions for breast cancer screening, pregnancy monitoring, and reproductive health imaging. They provide both funding and potential integration with GE's hardware platforms.

CVS Health Ventures backs digital health companies that can integrate with CVS's retail pharmacy and healthcare services network. They focus on telehealth platforms, medication adherence solutions, and consumer health applications targeting women's specific needs.

Roche Venture Fund invests in diagnostic companies developing blood tests, biomarkers, and laboratory technologies for women's health conditions. Their strategic value includes potential partnerships for commercializing diagnostic tests through Roche's global laboratory network.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you need to-the-point data on this market, you can download our latest market pitch deck here

How much total capital was invested globally in femtech during 2024 and what are the early 2025 trends?

Global femtech venture funding reached $2.6 billion in 2024, representing a 55% year-over-year increase and signaling strong investor confidence in women's health innovation.

When including related disease research specifically affecting women, total investment reached $10.7 billion in 2024, indicating that the broader women's health ecosystem attracts significantly more capital than pure-play femtech companies alone.

Early 2025 data suggests continued momentum with over $1.3 billion raised year-to-date through mid-2025, driven primarily by mega-rounds at Series B and later stages. This pace indicates 2025 could match or exceed 2024's record funding levels.

The funding increase reflects several factors: growing recognition of women's health as an underserved market, demonstrated commercial success of early femtech companies, and increasing corporate strategic interest. Institutional investors who previously avoided healthcare are now allocating significant portions of their portfolios to women's health startups.

Which early-stage femtech startups raised seed or Series A funding recently and what do they focus on?

Early-stage funding activity remains robust with startups tackling previously ignored aspects of women's health through innovative technology approaches.

Valerie raised £514,000 in pre-seed funding from LocalGlobe in May 2025, targeting perimenopause wellness through personalized coaching and symptom tracking. Their platform combines wearable data with lifestyle recommendations, addressing the gap between menstrual health apps and menopause-focused solutions.

UVISA secured $600,000 in seed funding from Emerge Health in May 2025 for vaginal infection therapy development. They're creating targeted treatments for bacterial vaginosis and yeast infections using novel delivery mechanisms that improve efficacy while reducing side effects.

Samphire Neuroscience raised $5 million in seed funding for menstrual pain neurotech solutions. Their approach uses targeted neurostimulation to interrupt pain signals, offering an alternative to hormonal treatments for women experiencing severe menstrual pain.

Calla Lily raised £1 million in seed funding from Seedcamp in April 2025, focusing on miscarriage prevention through early detection and intervention technologies. Their platform monitors pregnancy biomarkers and provides real-time risk assessment for expectant mothers.

Juniper Genomics' $4.6 million seed round from FemTech Canada and Arc Ventures supports development of comprehensive embryo screening technology. Their whole-genome approach provides more detailed genetic information than current preimplantation genetic testing methods.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

What are the investment forecasts and expectations for femtech going into 2026?

Analysts predict continued growth in femtech investment with several key trends driving increased capital allocation through 2026.

Fertility financing is expected to experience continued expansion as IVF access increases and insurance coverage improves. Companies like Future Family are creating new financing models that make expensive fertility treatments accessible to broader populations, attracting both venture capital and debt financing.

The menopause technology market represents a major growth opportunity with analysts estimating a $27 billion market opportunity by 2030. As baby boomers enter menopause and younger generations demand better healthcare options, investment in menopause-focused startups is expected to accelerate significantly.

M&A activity is predicted to increase as established healthcare companies seek differentiation through women's health capabilities. Corporate acquirers have significant cash reserves and recognize that women make 80% of healthcare decisions for their families, making femtech assets strategically valuable.

Government incentives are supporting early-stage R&D, with the UK's £6.1 billion research budget specifically including women's health priorities. Similar government initiatives in other countries are expected to stimulate early-stage innovation and de-risk private investment.

Overall funding is forecasted to rebound to 2021 peak levels by end of 2026, with analysts targeting $3 billion or more in annual femtech venture capital investment. This growth assumes continued commercial success of current portfolio companies and expanding recognition of women's health as a major market opportunity.

Conclusion

Sources

1. Everything Startups - FemTech Startups April 2025
2. Everything Startups - FemTech Startups May 2025
3. Everything Startups - FemTech Startups November 2024
4. Galen Growth - FemTech Digital Health Funding Trends
5. PR Newswire - Silicon Valley Bank Women's Health Report
6. Seedtable - FemTech Investors
7. Venquis - Why FemTech is Still Underfunded
8. Statista - FemTech Market Size Worldwide
9. Dealroom - FemTech Guide
10. Amboy Street VC - Women's Health M&A Overview
11. Grand View Research - FemTech Market Report
12. FemTech Canada - Funding
13. MHA - FemTech Growth 2025